AT86474 / Axcynsis Therap - LARVOL DELTA

Discovery of AT86474, a highly efficacious anti-ROR1 ADC utilizing a proprietary payload (AACR 2024) - "In vitro, the payload displays broad sub-nanomolar activity across multiple cancer cell lines, including those resistant to paclitaxel, DM1, MMAE and DXd. AT86474 was evaluated in a preclinical CDX mouse model of ovarian cancer, where substantial tumor growth inhibition was observed with two weekly doses at as low as 1 mg/kg. As ROR1 over-expression is also observed in many solid tumors, such as pancreatic, gastric, breast and lung cancers, the use of AT86474 can be expanded to benefit a large patient population."

Breast Cancer • Gastric Cancer • Hematological Malignancies • Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • ROR1